Skip to main content
. 2020 May 5;8(1):e000395. doi: 10.1136/jitc-2019-000395

Figure 1.

Figure 1

Schematic presentation of the patient selection flow. Eight hundred and fifty-seven patients were identified at 16 clinical centers. Thereof, 835 patients were eligible for analysis, including a subgroup of 223 patients with brain metastasis. ICI, immune checkpoint inhibition.